drugset / Trial / NCT03140956

Pharmacokinetic of Levodopa Study in Healthy Males

NCT03140956 ↗

Phase 1 Completed 20 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to investigate PK of levodopa in plasma after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104 and compared to the PK of standard IR and CR levodopa formulations in the same combination.

Timeline

Start
2017-04-19
Primary completion
2017-07-03
Completion
2017-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 20 mg —
Subject Carbidopa Unknown 25 mg —
Subject Carbidopa Unknown 65 mg —
Subject Levodopa Unknown 100 mg —
Subject ODM-104 Unknown 100 mg —

Indications